{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:14:46Z","timestamp":1790997286976,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009742","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000}}],"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["108518"],"award-info":[{"award-number":["108518"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009001","name":"University of York","doi-asserted-by":"crossref","award":["Consulting Agreement UYPROC_582"],"award-info":[{"award-number":["Consulting Agreement UYPROC_582"]}],"id":[{"id":"10.13039\/100009001","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>The development of vaccines against one or all forms of human leishmaniasis remains hampered by a paucity of investment, at least in part resulting from the lack of well-evidenced and agreed estimates of vaccine demand. Starting from the definition of 4 main use cases (prevention of visceral leishmaniasis, prevention of cutaneous leishmaniasis, prevention of post-kala-azar dermal leishmaniasis and treatment of post-kala-azar dermal leishmaniasis), we have estimated the size of each target population, focusing on those endemic countries where incidence levels are sufficiently high to justify decisions to adopt a vaccine. We assumed a dual vaccine delivery strategy, including a wide age-range catch-up campaign before the start of routine immunisation. Vaccine characteristics and delivery parameters reflective of a target product profile and the likely duration of the clinical development effort were considered in forecasting the demand for each of the four indications. Over a period of 10 years, this demand is forecasted to range from 300\u2013830 million doses for a vaccine preventing visceral leishmaniasis and 557\u20131400 million doses for a vaccine preventing cutaneous leishmaniasis under the different scenarios we simulated. In a scenario with an effective prophylactic visceral leishmaniasis vaccine, demand for use to prevent or treat post-kala-azar dermal leishmaniasis would be more limited (over the 10 years ~160,000 doses for prevention and ~7,000 doses for treatment). Demand would rise to exceed 330,000 doses, however, in the absence of an effective vaccine for visceral leishmaniasis. Because of the sizeable demand and potential for public health impact, a single-indication prophylactic vaccine for visceral or cutaneous leishmaniasis, and even more so a cross-protective prophylactic vaccine could attract the interest of commercial developers. Continuous refinement of these first-of-their kind estimates and confirmation of country willingness and ability to pay will be paramount to inform the decisions of policy makers and developers in relation to a leishmaniasis vaccine. Positive decisions can provide a much-needed contribution towards the achievement of global leishmaniasis control.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009742","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T14:36:31Z","timestamp":1632234991000},"page":"e0009742","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Human leishmaniasis vaccines: Use cases, target population and potential global demand"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-1127","authenticated-orcid":true,"given":"Stefano","family":"Malvolti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Malhame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten F.","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7450-543X","authenticated-orcid":true,"given":"Epke A.","family":"Le Rutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-4755","authenticated-orcid":true,"given":"Paul M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"pntd.0009742.ref001","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1080\/21645515.2018.1430542","article-title":"The global fight to develop antipoverty vaccines in the anti-vaccine era","volume":"14","author":"PJ Hotez","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"pntd.0009742.ref002","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"C Abbafati","year":"2020","journal-title":"Lancet"},{"key":"pntd.0009742.ref003","article-title":"Vaccine candidates for poor nations are going to waste","author":"DC Kaslow","year":"2018","journal-title":"Nature"},{"key":"pntd.0009742.ref004","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1080\/21645515.2019.1629254","article-title":"Running the Gauntlet\u201d: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a \u201cCall to Action.\u201d","volume":"15","author":"ME Bottazzi","year":"2019","journal-title":"Hum Vaccines Immunother."},{"key":"pntd.0009742.ref005","article-title":"Effective Vaccine Ecosystem,\u2014a reaserch project for the Wellcome Trust","author":"MMGH","year":"2020"},{"key":"pntd.0009742.ref006","article-title":"Key Facts\u2014Leishmaniasis.","author":"World Health Organization","year":"2020","journal-title":"WHO Website [Internet]"},{"key":"pntd.0009742.ref007","article-title":"Current and emerging medications for the treatment of leishmaniasis","author":"J Chakravarty","year":"2019","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"pntd.0009742.ref008","article-title":"Recent development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives","author":"F Alves","year":"2018","journal-title":"Clinical Microbiology Reviews."},{"key":"pntd.0009742.ref009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cix245","article-title":"Infectivity of Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of Concept in the Context of the Kala-azar Elimination Program in the Indian Subcontinent","volume":"65","author":"R Molina","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pntd.0009742.ref010","article-title":"Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study","author":"OP Singh","year":"2021","journal-title":"The Lancet Microbe"},{"key":"pntd.0009742.ref011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pt.2013.12.004","article-title":"Post kala-azar dermal leishmaniasis: An unresolved mystery","volume":"30","author":"D Mukhopadhyay","year":"2014","journal-title":"Trends Parasitol"},{"key":"pntd.0009742.ref012","article-title":"Post-Kala-Azar Dermal Leishmaniasis as a Reservoir for Visceral Leishmaniasis Transmission","author":"EA Le Rutte","year":"2019","journal-title":"Trends in Parasitology"},{"key":"pntd.0009742.ref013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1371\/journal.pntd.0005739","article-title":"A new perspective on cutaneous leishmaniasis\u2014Implications for global prevalence and burden of disease estimates","volume":"11","author":"F Bailey","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009742.ref014","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1017\/S0031182017000385","article-title":"Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: A systematic review","volume":"144","author":"PW Nassif","year":"2017","journal-title":"Parasitology"},{"key":"pntd.0009742.ref015","doi-asserted-by":"crossref","unstructured":"Pinart M, Jr R, Gas, Ce P, An SM, Reveiz L, et al. Pinart M, Rueda JR, Romero GAS, Pinz\u00f3n-Fl\u00f3rez CE, Osorio-Arango K, Silveira Maia-Elkhoury AN, Reveiz L, Elias VM, Tweed JA. 2020. doi: 10.1002\/14651858.CD004834.pub3 www.cochranelibrary.com","DOI":"10.1002\/14651858.CD004834.pub3"},{"key":"pntd.0009742.ref016","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/clinids\/13.5.1009","article-title":"Experimental Leishmaniasis in Humans: Review","volume":"13","author":"PC Melby","year":"1991","journal-title":"Rev Infect Dis"},{"key":"pntd.0009742.ref017","article-title":"Cutaneous leishmaniasis: Immune responses in protection and pathogenesis","author":"P Scott","year":"2016","journal-title":"Nature Reviews Immunology"},{"key":"pntd.0009742.ref018","first-page":"59","article-title":"Vaccines for Human Leishmaniasis: Where Do We Stand and What Is Still Missing? Leishmaniases as Re-emerging Diseases","author":"P Cec\u00edlio","year":"2018","journal-title":"InTech"},{"key":"pntd.0009742.ref019","article-title":"Leishmania vaccines entered in clinical trials: A review of literature.","author":"M Moafi","year":"2019","journal-title":"International Journal of Preventive Medicine"},{"key":"pntd.0009742.ref020","first-page":"1","article-title":"A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing","volume":"11","author":"WW Zhang","journal-title":"Nat Commun. 2020"},{"key":"pntd.0009742.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-016-1553-y","article-title":"Possibilities and challenges for developing a successful vaccine for leishmaniasis","volume":"9","author":"S Srivastava","year":"2016","journal-title":"Parasites and Vectors"},{"key":"pntd.0009742.ref022","article-title":"Characterization of a new Leishmania major strain for use in a controlled human infection model.","author":"H Ashwin","year":"2021","journal-title":"Nat Commun."},{"key":"pntd.0009742.ref023","first-page":"7","article-title":"Leishmaniasis worldwide and global estimates of its incidence","author":"J Alvar","year":"2012","journal-title":"PLoS One"},{"key":"pntd.0009742.ref024","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4161\/hv.6.9.12587","article-title":"Forecasting dengue vaccine demand in disease endemic and non-endemic countries","volume":"6","author":"A Amarasinghe","year":"2010","journal-title":"Hum Vaccin"},{"key":"pntd.0009742.ref025","first-page":"36","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) vaccine: A global assessment of demand and supply balance","author":"T Cernuschi","year":"2018","journal-title":"Vaccine"},{"key":"pntd.0009742.ref026","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.vaccine.2008.10.069","article-title":"Forecasting demand for Hib-containing vaccine in the world\u2019s poorest countries: A 4-year prospective experience","volume":"27","author":"PLF Zuber","year":"2009","journal-title":"Vaccine"},{"key":"pntd.0009742.ref027","article-title":"Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India.","author":"S Jervis","year":"2017","journal-title":"Parasit Vectors"},{"key":"pntd.0009742.ref028","first-page":"1","article-title":"Global Distribution Maps of the Leishmaniases","volume":"2010","author":"DM Pigott","year":"2014","journal-title":"Elife"},{"key":"pntd.0009742.ref029","first-page":"22","article-title":"Control of the leishmaniases","author":"World Health Organization","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"key":"pntd.0009742.ref030","unstructured":"Drug for Neglected Disease Initiative. DNDi\u2014NewsLetter. [cited 2 Jan 2020]. Available: https:\/\/www.dndi.org\/newsletters\/n18\/4_1.php"},{"key":"pntd.0009742.ref031","unstructured":"World Health Organization. WHO | New leishmaniasis country profiles based on routine surveillance data. [cited 2 Jan 2020]. Available: https:\/\/www.who.int\/neglected_diseases\/news\/New_leishmaniasis_country_profiles_based_on_routine_surveillanc\/en\/"},{"key":"pntd.0009742.ref032","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1017\/S0031182018000471","article-title":"Leishmaniasis: Current challenges and prospects for elimination with special focus on the South Asian region","volume":"145","author":"ND Karunaweera","year":"2018","journal-title":"Parasitology"},{"key":"pntd.0009742.ref033","unstructured":"United Nations\u2014Department for Economic and Social Affairs. World Population Prospects\u2014Population Division\u2014United Nations. In: World Population Prospects 2019 [Internet]. [cited 2 Jan 2020]. Available: https:\/\/population.un.org\/wpp\/Download\/Standard\/Population\/"},{"key":"pntd.0009742.ref034","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cid\/ciy891","article-title":"Quantifying the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies","volume":"69","author":"D Mondal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pntd.0009742.ref035","article-title":"Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.","author":"EE Zijlstra","year":"2017","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"pntd.0009742.ref036","article-title":"Clinco-epidemiologic study of cutaneous leishmaniasis in bikaner, Rajasthan, India","author":"N Aara","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009742.ref037","article-title":"Searching for cutaneous leishmaniasis in tribals from Kerala, India.","author":"S Simi","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"pntd.0009742.ref038","author":"PAHO","year":"2016","journal-title":"Leishmaniases\u2014Epidemiological Report of the Americas\u2014No4"},{"key":"pntd.0009742.ref039","unstructured":"Drug for Neglected Disease Initiative. About Leishmaniasis\u2013DNDi. 2019 [cited 31 Dec 2019]. Available: https:\/\/www.dndi.org\/diseases-projects\/leishmaniasis\/"},{"key":"pntd.0009742.ref040","article-title":"Visceral Leishmaniasis in Ethiopia: An Evolving Disease.","author":"S Leta","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009742.ref041","first-page":"1","article-title":"Effects of El Ni\u00f1o-Southern oscillation on human visceral leishmaniasis in the Brazilian State of Mato Grosso do Sul","volume":"115","author":"S Neto AB da","year":"2020","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pntd.0009742.ref042","article-title":"Visceral leishmaniasis cyclical trends in Bihar, India\u2013Implications for the elimination programme","author":"RM Deb","year":"2018","journal-title":"Gates Open Res"},{"key":"pntd.0009742.ref043","article-title":"A report on current global access to new childhood vaccines","author":"Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC).","year":"2019"},{"key":"pntd.0009742.ref044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0008468","article-title":"The potential impact of human visceral leishmaniasis vaccines on population incidence","volume":"14","author":"EA Le Rutte","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009742.ref045","author":"World Health Organization","year":"2020","journal-title":"MI4A - Market Information for Access to Vaccines"},{"key":"pntd.0009742.ref046","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post kala azar dermal leishmaniasis patients in Sudan","author":"B Younis","year":"2020","journal-title":"medRxiv"},{"key":"pntd.0009742.ref047","article-title":"Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum","author":"A Romano","year":"2015","journal-title":"J Immunol"},{"key":"pntd.0009742.ref048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-3305-7-3","article-title":"Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis","volume":"7","author":"L Ramirez","year":"2014","journal-title":"Parasites and Vectors"},{"key":"pntd.0009742.ref049","author":"World Health Organization","journal-title":"Immunization Coverage. In: World Health Data Platform. 2020"},{"key":"pntd.0009742.ref050","article-title":"Financing vaccines in the 21st century: Recommendations from the National Vaccine Advisory Committee.","author":"AR Hinman","year":"2005","journal-title":"American Journal of Preventive Medicine"},{"key":"pntd.0009742.ref051","article-title":"Summary Measles SIA 2000\u20132020","author":"World Health Organization","year":"2020"},{"key":"pntd.0009742.ref052","article-title":"Eliminating visceral leishmaniasis in South Asia: The road ahead","author":"S Rijal","year":"2019","journal-title":"BMJ (Online)."},{"key":"pntd.0009742.ref053","article-title":"Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence","author":"S Sundar","year":"2018","journal-title":"Expert Review of Anti-Infective Therapy."},{"key":"pntd.0009742.ref054","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","author":"SL James","year":"2018","journal-title":"Lancet"},{"key":"pntd.0009742.ref055","article-title":"World Bank Country and Lending Groups\u2013World Bank Data Help Desk.","author":"World Bank","journal-title":"In: Country classification [Internet]."},{"key":"pntd.0009742.ref056","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1377\/hlthaff.2011.0403","article-title":"Economic perspectives on the advance market commitment for pneumococcal vaccines","volume":"30","author":"CM Snyder","year":"2011","journal-title":"Health Aff"},{"key":"pntd.0009742.ref057","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1371\/journal.pntd.0006837","article-title":"Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years","volume":"12","author":"PL Olliaro","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009742.ref058","article-title":"Accelerating typhoid conjugate vaccine introduction: What can be learned from prior new vaccine introduction initiatives?","author":"LP Jamka","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pntd.0009742.ref059","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4269\/ajtmh.16-0184","article-title":"Meeting report: Visceral leishmaniasis control and elimination: Is there a role for vaccines in achieving regional and global goals?","volume":"95","author":"AX Mo","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009742.ref060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/trstmh\/trv039","article-title":"Development of Leishmania vaccines in the era of visceral leishmaniasis elimination","volume":"109","author":"CR Engwerda","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009742.ref061","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S2214-109X(14)70318-3","article-title":"Research priorities for elimination of visceral leishmaniasis","volume":"2","author":"G Matlashewski","year":"2014","journal-title":"Lancet Glob Heal"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009742","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T16:17:45Z","timestamp":1633105065000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009742"}},"subtitle":[],"editor":[{"given":"Dhafer","family":"Laouini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009742","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.09.21260268","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]}}}